CVD risk assessment and management
Exam Tips
- Use QRISK3 for ages 25-84 years, but do not apply it to people with established CVD, type 1 diabetes, significant CKD/albuminuria, familial hypercholesterolaemia, or age >=85 years (already high risk).
- For QRISK input, remember: age, sex, ethnicity, postcode deprivation, smoking, BP, BMI, cholesterol/HDL ratio, family and comorbidity data.
- A QRISK <10% is not 'no risk': give lifestyle intervention, optimise comorbidities, and usually repeat formal assessment in about 5 years (earlier if major clinical change).
- In UK OSCEs, score highly by explaining absolute risk clearly, checking readiness to change, and agreeing a shared management plan rather than giving one-way advice.
- If a patient has symptoms suggestive of active CVD, pivot from risk scoring to diagnostic assessment and urgent pathway as appropriate.
Definition
Cardiovascular disease (CVD) risk assessment is the structured estimation of a person’s future likelihood of atherosclerotic cardiovascular events (for example myocardial infarction, stroke, TIA, peripheral arterial disease, or aortic disease) before clinical disease is established. In UK primary care, this is usually done with QRISK3 (age 25-84 years) as part of primary prevention, combining clinical history, examination data, and blood results to guide shared decisions on lifestyle change and preventive treatment.
Pathophysiology
Most preventable CVD risk relates to progressive atherogenesis: endothelial dysfunction allows lipid entry into the arterial intima, oxidation and inflammation drive foam-cell formation, and fibrofatty plaque develops with arterial narrowing and reduced compliance. Plaques may remain flow-limiting (causing chronic ischaemia) or rupture/erode, triggering thrombosis and acute occlusion (for example acute coronary syndrome or ischaemic stroke). Risk factors such as smoking, hypertension, diabetes, CKD, dyslipidaemia, systemic inflammation, and adverse social determinants accelerate this process. See Figure: atherosclerotic plaque evolution (fatty streak to complicated plaque) in standard cardiovascular pathology chapters.
Risk Factors
- Increasing age (especially >50 years)
- Male sex (earlier onset on average)
- Family history of premature CVD
- Ethnicity (higher risk in South Asian and sub-Saharan African populations)
- Smoking
- Low HDL cholesterol
- High non-HDL cholesterol
- Physical inactivity/sedentary lifestyle
- Unhealthy diet
- Alcohol intake above recommended limits
- Overweight/obesity
- Hypertension
- Diabetes mellitus (including pre-diabetes/metabolic syndrome)
- Chronic kidney disease (including albuminuria/reduced eGFR)
- Atrial fibrillation
- Inflammatory disease (for example rheumatoid arthritis, SLE)
- Serious mental illness/PTSD and chronic anxiety states
- Periodontitis
- Premature menopause, PCOS, and prior pre-eclampsia
- Socioeconomic deprivation and social isolation
Clinical Features
Symptoms
- Usually none (risk assessment is commonly performed in asymptomatic people)
- History may reveal lifestyle risk factors (smoking, inactivity, excess alcohol, poor diet)
- If exertional chest pain, focal neurological symptoms, or claudication are present, consider established CVD rather than isolated risk-state assessment
Signs
- Raised blood pressure on repeated measurement
- Increased BMI and/or central adiposity
- Features of comorbidity influencing risk (for example diabetic or CKD indicators in records)
Investigations
Management
Lifestyle Modifications
- Use a systematic case-finding approach (not mainly opportunistic screening) and review risk regularly; in England, NHS Health Check is offered every 5 years for eligible adults aged 40-74 years
- Communicate risk in shared-decision style: baseline risk, modifiable contributors, and absolute benefit of change
- Smoking cessation support (behavioural plus pharmacotherapy where appropriate)
- Mediterranean-style dietary pattern, weight reduction if overweight, and reduced saturated/trans fats
- Regular physical activity (for most adults: at least 150 minutes/week moderate intensity plus strength work)
- Reduce alcohol to UK low-risk guidance
- Optimise comorbidities (hypertension, diabetes, CKD, dyslipidaemia, inflammatory disease)
Pharmacological Treatment
Lipid lowering for primary prevention
- Atorvastatin 20 mg orally once daily (typical first-line primary prevention dose)
Usually considered when QRISK3 10-year risk is >=10% after shared decision-making; check baseline lipids, LFTs, and consider secondary causes. Contraindications/safety: avoid in pregnancy and breastfeeding; caution in active liver disease; discuss myalgia risk and check CK if severe muscle symptoms; interactions include strong CYP3A4 inhibitors and excess grapefruit juice.
Adjuncts when statin intolerance or inadequate response in selected patients
- Ezetimibe 10 mg orally once daily
Consider according to lipid specialist guidance/local pathway if statin not tolerated or targets not approached. Monitor liver enzymes if combined with statin; avoid in active hepatic disease when used with statin.
Blood pressure reduction (risk-factor control, not solely by QRISK value)
- Ramipril 2.5 mg once daily initially, titrated (commonly up to 10 mg once daily)
- Amlodipine 5 mg once daily initially, titrated to 10 mg once daily
Treat diagnosed hypertension per UK hypertension guidance. Safety: ACE inhibitors are teratogenic (avoid in pregnancy), can cause hyperkalaemia and renal impairment; check U&E/creatinine after initiation and dose changes.
Complications
- Myocardial infarction
- Ischaemic stroke
- Transient ischaemic attack
- Peripheral arterial disease with claudication/critical limb ischaemia
- Aortic aneurysm/dissection events
- Chronic kidney disease progression and multimorbidity-related disability
- Premature cardiovascular death
Prognosis
Prognosis is strongly risk-factor dependent: untreated clustered risk factors substantially increase lifetime event burden, while sustained modification (especially smoking cessation, BP control, and lipid lowering where indicated) reduces first-event risk. At population level in the UK, CVD remains a major cause of mortality despite long-term improvements in age-standardised death rates, so early identification and repeated review are clinically meaningful.
Sources & References
🏥BMJ Best Practice(2)
✅NICE Guidelines(1)
- CVD risk assessment and management[overview]
📖Textbook References(4)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1603, 1604)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 480)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1729, 1730)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1608, 1609)[context]